Biocon

Biosimilars Up 54 per cent; Research services up 23 per cent; Generics up 18 per cent

The US Food and Drug Administration (USFDA) issues a Complete Response Letter (CRL) to convey to a company that its initial review…

This is a phase-II randomised, double-blind, parallel-group, placebo and active-controlled (adalimumab), two-treatment period…

Biocon and Dr Reddy's have been recognised by 'Science' magazine in the top 10 and top 20 employers list, respectively

Dr Rakesh Bhasin, Vice President and Head – R&D (Formulations), started his presentation by introducing 3D printing to the…

FY22 revenue at Rs 8,397 crores, up 14 per cent; core EBITDA up 18 per cent at Rs 2,669 crores; PBT (before Exceptional Item) at…

Shaw is among the 80 luminaries to be appointed to the RSE’s Fellowship this year

Kiran Mazumdar Shaw, Chairperson, Biocon, and Biocon Biologics, shares her reaction to the union budget 2022 released today

Under the terms of this agreement, Tabuk Pharmaceuticals will hold the marketing authorisation for select speciality products of…

The product is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant and is available…